

**APPENDIX B**  
**CLEAN COPY OF AMENDED CLAIMS**

Claim 19. A method for radiosensitizing cancer cells, comprising the step of  
delivering to said cancer cells an effective dose of an expressible nucleic acid encoding a  
dominant negative mutant epidermal growth factor.

Claim 20. The method of claim 19, wherein said dominant negative mutant epidermal growth factor  
is EGFR-CD533.